Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the low priced stocks to buy with high upside potential. On December 8, Wave ...

Vial's INHBE siRNA is a first-in-class, liver-targeted (GalNAc-conjugated) siRNA therapy that silences INHBE and its gene product, Activin E -- Leading key opinion leaders (KOL ...

Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% ...

It has only been 5 years since Tom Tuschl and colleagues showed that the RNA interference (RNAi) pathway was functional in cultured mammalian cells, and that it was possible to trigger this process to ...

Phio Pharmaceuticals ( ($PHIO) ) has provided an announcement. On December 23, 2025, Phio Pharmaceuticals announced that the U.S. Food and Drug ...

This Research Topic invites high-impact research that advances nanotechnology-enabled antiviral interventions across the pipeline from molecular design to ...

SHANGHAI and SANTA BARBARA, Calif., Dec. 17, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in next-generation RNAi medicines, today announced the ...

NRXBF READ THE FULL NRXBF RESEARCH REPORT NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to ...

Rona Therapeutics, a global leader in next-generation RNAi medicines, today announced the submission of RN5681 to the Australian Human Research Ethics Committee (HREC), advancing the company's first b ...

Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) ...

Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026 King of Prussia, Pennsylvania–(Newsfile Corp. – December 23, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: ...